[Quality of life in inflammatory bowel disease patients].
OBJECTIVE
To study the quality of life (QOL) patients with inflammatory diseases (IBD), gender and age characteristics of QOL, as well as its dynamics under the influence of biological and standard therapy.


METHODS
Investigation of QOL using the SF-36 was performed on 90 patients with IBD, among them 35 with Crohn's disease, 55--ulcerative colitis. Mean age 35.2 +/- 1.2 years, men--53, women--37. Severity of symptoms of IBD (by Best and Truelove): mild--7 (7.7%), moderate--69 (76.6%), severe--14 (15.7%), extraintestinal manifestations were present in 34 (37.8%) patients. After a year was conducted the survey in 31 patients (group 1) after standard therapy with 5-aminosalicylic acid (5-ASA), corticosteroids (GCS), 29 patients (Group 2)--after systemic transplantation of mesenchymal stromal cells (MSCs) of 27 patients (group 3)--Treatment with infliximab (IFX). The results. QOL was reduced in all patients in all scales of the questionnaire, including adverse changes in the psycho-emotional and social spheres. In the dynamics under the influence of the therapy, especially in achieving complete clinical and endoscopic remission, tendency to improve the performance of most QOL was more pronounced in patients with IBD treated with biological therapy MSCs and inflation, compared with patients receiving standard therapy. Identified gender differences in indicators of QOL that requires to develop psychosocial rehabilitation programs that take into account these differences. It is concluded that the need for participation of psychologists and neuropsychiatrists gastroenterologist in joint management and treatment of IBD. Was concluded the necessity of psychologists and neuropsychiatrists and gastroenterologist participation in joint management and treatment of IBD.
O V
OV
Kniazev
O N
ON
Boldyreva
A I
AI
Parfenov
L I
LI
Efremov
M G
MG
Guseĭnzade
I N
IN
Ruchkina
A G
AG
Konopliannikov
V É
VÉ
Sagynbaeva
I I
II
Gribanov
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D000069285:Infliximab; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage*; D045164:Mesenchymal Stem Cell Transplantation; D008875:Middle Aged; D011788:Quality of Life; D014184:Transplantation, Homologous
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D019804:Mesalamine; D000069285:Infliximab